Immune Response BioPharma and investors

Immune Response BioPharma's David Buswell made some interesting comments recently in regards to House Resolution 1179 (H. Res 1179)  saying that it was wasted taxpayer dollars. He seems to take the moral high ground in the following statements.

“These are really wicked bad people and want to waste your taxpayer dollars on obsolete and junk science. Everyone knows the way to defeat a virus is through the weakened vaccine. They are terrified of my efforts to get REMUNE approved and have gone so far as to trick me on to a conference call and both of them yelled at me for over two hours. These people are crazy and just want to go on needless conferences wasting your taxpayer dollars and junk science and toxic solutions. I pray that God takes action against these evil people”

“They have done their best to discredit my efforts and are trying their best to derail patients from getting the REMUNE vaccine. REMUNE can solve the majority of the HIV/AIDS issues. And I am not afraid of these people they are cowards who do not want a real solution to the pandemic. They just want to continue their lifestyles of wasting taxpayer dollars, and big pharma too has no reason to want REMUNE approved they lose billions of dollars. I restarted Immune Response to save lives I receive no salary. The IP and trademarks were abandoned the company was dissolved and I restarted this company because I believe the science is sound and I won’t be pushed around by wall St.. or these evil people. I am not afraid of cowards”

I would suggest that the best way to advance the research conducted by Immune Response Corportation and Orchestra Therapeutics (OCHT) is to honor the shareholders of OCHT which still trades and whose investors still have rights. The people in charge of managing IMNR and OCHT might have been dishonest, but their investors were hard working people who invested in what they thought was an honestly operated company. Immune Response BioPharma should recognize the shareholders in OCHT by giving them stock in their new company or else paying them compensation for their investments which created the research David Buswell is now trying to bring to market. If you are going to take research from a company that had a reputation for trying to prevent negative test results from being printed not to mention the management disaster that was Immune Response/Orchestra then you better start out on the right foot and do it in a fair and honest manner from day one.